



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. Serial No.: 10/671,304

Inventors: GEDULIN, et al

Filed: September 24, 2003

Title: TREATMENT OF PANCREATITIS WITH
AMYLIN

Confirmation No.: 8486

TC/A.U.: 1655

Examiner: WINSTON, Randall O.

Atty. Docket No.: 0101-UTL-0

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS:


In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, Applicants submit copies of the references listed on the attached PTO Form PTO/SB/08A for consideration by the U.S. Patent and Trademark Office in the above-entitled application and to be made of record herein. In accordance with 37 C.F.R. 1.98, copies of cited U.S. Patents and U.S. Patent Application Publications are not included herewith. Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08A, indicating that the information has been considered and made of record herein.

The references are being cited only in the interests of candor and without any admission that they constitute statutory prior art or contain matter which anticipates the invention or which would render the same obvious, either singly or in combination, to a person of ordinary skill in the art.

CERTIFICATE OF EXPRESS MAILING UNDER 37 C.F.R. 1.10

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being deposited with the United States Postal Service for "Express Mail Post Office to Addressee" service, Express Mail Label No. EV 426999792 US, in an envelope addressed to Mail Stop Amendment, Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

10/18/06
Date of Deposit


Signature of Person Mailing Paper


Deborah W. Sykes
Name of Person Mailing Paper

The Commissioner is hereby authorized to charge Deposit Account No. 01-0535 the amount of \$180.00 as set forth in 37 C.F.R. 1.17(p). Applicants believe no additional fees are due. If Applicants are in error, the Commissioner is hereby authorized to charge any underpayment or credit any overpayment to Deposit Account No. 01-0535. Additionally, the Commissioner is hereby authorized to charge payment or credit overpayment of any fees during the pendency of this application to Applicant's Deposit Account No. 010535.

Respectfully Submitted

AMYLIN PHARMACEUTICALS, INC.

Dated: 18 October 2006



Karen R. Zachow, Ph.D.
Registration No. 46,332

AMYLIN PHARMACEUTICALS, INC.
9373 Towne Centre Drive
San Diego, CA 92121
Telephone: (858) 552-2200
Facsimile: (858) 552-1936



PTO/SB/08A (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1

of 2

Complete if Known

Application Number	10/671,304
Filing Date	September 24, 2003
First Named Inventor	GEDULIN, et al.
Art Unit	1655
Examiner Name	WINSTON, Randall O.
Attorney Docket Number	101-UTL

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	001	US- 2003/0092606	05/15/2003	L'ITALIEN, et al.	
	002	US- 5,124,314	06/23/1992	COOPER, Garth J.S.	
	003	US- 5,234,906	08/10/1993	YOUNG, et al.	
	004	US- 5,264,372	11/23/1993	BEAUMONT, et al.	
	005	US- 5,677,279	10/14/1997	YOUNG, Andrew A.	
	006	US- 5,686,411	11/11/1997	GAETA, et al.	
	007	US- 5,998,367	12/07/1999	GAETA, et al.	
	008	US- 6,114,304	09/05/2000	KOLTERMAN, et al.	
	009	US- 6,410,511	06/25/2002	L'ITALIEN, et al.	
	010	US- 6,610,824	08/26/2003	GAETA, et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	011	EP 0289287	01/28/1998			
	012	WO 93/10146	05/27/1993			

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/671,304
		Filing Date	September 24, 2003
		First Named Inventor	GEDULIN, et al.
		Art Unit	1655
		Examiner Name	WINSTON, Randall O.
Sheet 2	of 2	Attorney Docket Number	0101-UTL-0

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	013	COOPER, et al, "Amylin Found in Amyloid Deposits in Human Type 2 Diabetes Mellitus..." Proc. Acad. Sci. USA (1988) 85 pp 7763-7766	
	014	COOPER, et al, "The Amylin Superfamily: A Novel Grouping of Biologically Active Polypeptides Related to the Insulin A-Chain" Prog Growth Factor Res. (1989) 1 pp 99-105	
	015	GEDULIN, et al, "Dose-Response for Glucagonostatic Effect of Amylin in Rats" Metabolism (1997) 46:1 pp67-70	
	016	GEDULIN, et al, "Amylin Inhibits Pentagastrin-Stimulated Gastric Acid Secretion and Protects Against Ethanol-Induced..." Diabetologia (1997) 40:A299 (Abstract 1177)	
	017	LEIGHTON, et al, "Pancreatic Amylin and Calcitonin Gene-Related Peptide Cause Resistance to Insulin in Skeletal Muscle in vitro" Nature (1988) 335:6191 pp 632-635	
	018	MUNSON, et al, "Ligand: A Versatile Computerized Approach for Characterization of Ligand-Binding Systems" Anal Biochem (1980) 107 pp 220-239	
	019	OGAWA, et al, "Amylin Secretion from the Rat Pancreas and its Selective Loss After Streptozotocin Treatment" J Clin Invest (1990) 85 pp 973-976	
	020	SILVESTRE, et al, "Inhibitory Effect of Rat Amylin on the Insulin Responses to Glucose and Arginine in the Perfused Rat Pancreas" Regul Pept (1990) 31 pp 23-31	
	021	WARZECHA, et al, "Effect of Sensory Nerves and CGRP on the Development of Caerulein-Induced Pancreatitis and Pancreatic Recovery" J. Physio and Pharm (2001) 52:4 pp679-704	
	022	WARZECHA, et al, " The Influence of Sensory Nerves and CGRP on the Pancreatic Regeneration After Repeated Episodes of Acute..." J Physio and Pharma (2000) 51:3 pp 449-461	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.